Ligand Pharmaceuticals - 15 Year Dividend History | LGND
Historical dividend payout and yield for Ligand Pharmaceuticals (LGND) since 2009. The current TTM dividend payout for Ligand Pharmaceuticals (LGND) as of November 19, 2024 is $0.00. The current dividend yield for Ligand Pharmaceuticals as of November 19, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.113B |
$0.131B |
|
Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. Ligand has merged with CyDex. By this, it added an antibody-generating platform, OmniAb, to the company's portfolio. Its other technology platforms include antigen discovery platform & protein expression platform. All these technologies have created a strong platform for Ligand to seek new licenses and partnerships. Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Celgene, Gilead & Lilly, etc. The company continues to buy smaller companies to increase its technology platforms.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
